在96%的抗药性艾滋病毒患者中,一种新的单一流感艾滋病毒治疗使病毒水平保持在较低水平,为老年病人提供了更简单、更安全的选择。 A new single-pill HIV treatment kept virus levels low in 96% of people with drug-resistant HIV, offering a simpler, safer option for older patients.

根据CROI 2026上提出的第三期试验,一种新的单片药片治疗,结合了比克特格拉维尔和莱纳卡帕维尔 (BIC/LEN),在近96%的耐药HIV患者中有效地维持了病毒抑制,这些患者之前需要复杂的多片药片治疗方案. A new single-pill HIV treatment combining bictegravir and lenacapavir (BIC/LEN) effectively maintained viral suppression in nearly 96% of people with drug-resistant HIV who previously needed complex, multi-pill regimens, according to a phase 3 trial presented at CROI 2026. 这项研究有来自15个国家的550多名参与者参加,其中大多数有数十年的艾滋病毒历史、基本健康状况和60岁中位年龄,这是迄今为止任何艾滋病毒试验中最年长的年龄。 The study included over 550 participants across 15 countries, most with decades-long HIV histories, underlying health conditions, and median age of 60—the oldest in any HIV trial to date. 新的疗法没有显示新的抗药性,没有重大的安全关切,脂质特征得到改善,治疗满意度提高,为历史上服务不足的群体提供了更简单、更方便的选择。 The new regimen showed no new drug resistance, no major safety concerns, improved lipid profiles, and higher treatment satisfaction, offering a simpler, more convenient option for a historically underserved group. 长期研究仍在进行中。 Long-term studies are ongoing.